secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2024-05-23T23:59:59+00:00
Accession:  0001628280-24-024920
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics receives Nasdaq delisting notice for negative stockholders' equity of $112.6M
--------------------------------------------------------------------------------

- Reported stockholders' equity of negative $112.6M in Q1 2024 10-Q, below $2.5M minimum.
- Has 45 days (until July 5, 2024) to submit a compliance plan to Nasdaq Staff.
- If plan accepted, Staff may grant up to 180-day extension to regain compliance.
- No immediate effect on listing; common stock continues trading on Nasdaq under AVTX.
- Company evaluating options; no assurance of regaining compliance or avoiding delisting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024024920/0001628280-24-024920-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024024920/avtx-20240520.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-024920

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer